Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and Therapy

被引:8
|
作者
Serfling, Sebastian E. [1 ]
Hartrampf, Philipp E. [1 ]
Zhi, Yingjun [2 ]
Higuchi, Takahiro [1 ,3 ]
Rowe, Steven P. [4 ]
Bundschuh, Lena [5 ]
Essler, Markus [5 ]
Buck, Andreas K. [1 ]
Bundschuh, Ralph Alexander [5 ]
Werner, Rudolf A. [1 ,4 ]
机构
[1] Julius Maximilian Univ Wurzburg, Dept Nucl Med, Univ Hosp Wurzburg, Wurzburg, Germany
[2] Julius Maximilian Univ Wurzburg, Dept Otorhinolaryngol Aesthet & Reconstruct Head, Wurzburg, Germany
[3] Okayama Univ, Fac Med Dent & Pharmaceut Sci, Okayama, Japan
[4] Johns Hopkins Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD USA
[5] Univ Hosp Bonn, Dept Nucl Med, Venusberg Campus 1, D-53127 Bonn, Germany
基金
日本学术振兴会;
关键词
fibroblast activation protein inhibitor; FAPI; molecular imaging; theranostics; endoradiotherapy; RADS; CANCER; CLASSIFICATION;
D O I
10.1097/RLU.0000000000004189
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives Fibroblast activation protein (FAP) has emerged as a novel target for FAP inhibitor (FAPI)-directed molecular imaging and endoradiotherapy (ERT). We aimed to assess the interobserver agreement rates for interpretation of Ga-68-FAPI-4 PET/CT and decision for ERT. Patients and Methods A random order of Ga-68-FAPI-4 PET/CTs from 49 oncology patients were independently interpreted by 4 blinded readers. Per scan, visual assessment was performed, including overall scan impression, number of organ/lymph node (LN) metastases, and number of affected organs/LN regions. Moreover, a maximum of 3 target lesions, defined as largest in size and/or most intense, per organ compartment were identified, which allowed for an additional quantitative interobserver assessment of LN and organ lesions. To investigate potential reference tissues, quantification also included unaffected liver parenchyma and blood pool. Readers also had to indicate whether FAPI-directed ERT should be considered (based on intensity of uptake and widespread disease). Interobserver agreement rates were evaluated using intraclass correlation coefficients (ICCs) and interpreted according to Cicchetti (with 0.4-0.59 indicating fair, and 0.6-0.74 good, agreement). Results On a visual basis, the agreement rate for an overall scan impression was fair (ICC, 0.42; 95% confidence interval [CI], 0.27-0.57). The concordance rate for number of affected LN areas was also fair (ICC, 0.59; 95% CI, 0.45-0.72), whereas the number of LN metastases, number of affected organs, and number of organ metastases achieved good agreement rates (ICC, >= 0.63). In a quantitative analysis, concordance rates for LN were good (ICC, 0.70; 0.48-0.88), but only fair for organ lesions (ICC, 0.43; 0.26-0.60). In regards to background tissues, ICCs were good for unaffected liver parenchyma (0.68; 0.54-0.79) and fair for blood pool (0.43; 0.29-0.58). When readers should decide on ERT, concordance rates were also fair (ICC, 0.59; 95% CI, 0.46-0.73). Conclusions For FAPI-directed molecular imaging and therapy, a fair to good interobserver agreement rate was achieved, supporting the adoption of this radiotracer for clinical routine and multicenter trials.
引用
收藏
页码:512 / 516
页数:5
相关论文
共 50 条
  • [21] Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond
    Mengting Li
    Muhsin H. Younis
    Yongxue Zhang
    Weibo Cai
    Xiaoli Lan
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 2844 - 2868
  • [22] Fibroblast Activation Protein Inhibitor Theranostics Preclinical Combination Treatment
    Lueckerath, Katharina
    Trajkovic-Arsic, Marija
    Mona, Christine E.
    PET CLINICS, 2023, 18 (03) : 409 - 418
  • [23] Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond
    Li, Mengting
    Younis, Muhsin H.
    Zhang, Yongxue
    Cai, Weibo
    Lan, Xiaoli
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (08) : 2844 - 2868
  • [24] Substrate Study for Dihydroxyboryl Astatine Substitution Reaction with Fibroblast Activation Protein Inhibitor (FAPI)
    Aso, Ayaka
    Kaneda-Nakashima, Kazuko
    Nabetani, Hinako
    Kadonaga, Yuichiro
    Shirakami, Yoshifumi
    Watabe, Tadashi
    Yoshiya, Taku
    Mochizuki, Masayoshi
    Koshino, Yuki
    Ooe, Kazuhiro
    Kawakami, Atsuko
    Jinno, Naoya
    Toyoshima, Atsushi
    Haba, Hiromitsu
    Wang, Yang
    Cardinale, Jens
    Giesel, Frederik L.
    Shimoyama, Atsushi
    Fukase, Koichi
    CHEMISTRY LETTERS, 2022, 51 (11) : 1091 - 1094
  • [25] Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics-Where We Are at and Where We Are Heading: A Systematic Review
    Sidrak, Marko Magdi Abdou
    De Feo, Maria Silvia
    Corica, Ferdinando
    Gorica, Joana
    Conte, Miriam
    Filippi, Luca
    Schillaci, Orazio
    De Vincentis, Giuseppe
    Frantellizzi, Viviana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [26] Inhibitor-conjugated harmonic nanoparticles targeting fibroblast activation protein
    De Matos, Raphael
    Vuilleumier, Jeremy
    Mas, Christophe
    Constant, Samuel
    Staedler, Davide
    Gerber, Sandrine
    RSC ADVANCES, 2019, 9 (54) : 31659 - 31669
  • [27] The Potential of Fibroblast Activation Protein-Targeted Imaging as a Biomarker of Cardiac Remodeling and Injury
    Mayola, Maday Fernandez
    Thackeray, James T.
    CURRENT CARDIOLOGY REPORTS, 2023, 25 (06) : 515 - 523
  • [28] Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions
    Ora, Manish
    Soni, Neetu
    Nazar, Aftab Hasan
    Dixit, Manish
    Singh, Rohit
    Puri, Savita
    Graham, Michael M.
    Gambhir, Sanjay
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (07) : 1001 - 1008
  • [29] Preclinical assessment of fibroblast activation protein as a target for antitumor therapy
    Hayward, Simon W.
    FUTURE ONCOLOGY, 2010, 6 (03) : 347 - 349
  • [30] Molecular imaging of fibroblast activation in multiple non-ischemic cardiomyopathies
    Wang, Jingnan
    Huo, Li
    Lin, Xue
    Fang, Ligang
    Hacker, Marcus
    Niu, Na
    Li, Xiang
    EJNMMI RESEARCH, 2023, 13 (01)